COMMUNIQUÉS West-GlobeNewswire

Leading National Specialty Pharmacy Selects ScriptMed® Cloud for Advanced Pharmacy Capabilities
20/12/2018
Top 10 Specialty Pharmacy to Implement the Inovalon ONE® Platform Cloud-Based Capabilities to Drive Increased Efficiencies and Outcomes BOWIE, Md., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Inovalon (Nasdaq: INOV), a leading [...]
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
20/12/2018
FRAMINGHAM, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel liquid, gel and solid hemostatic and wound care devices, will be featured as a [...]
Uptick Newswire Hosts the CEO of Premier Biomedical, Inc. to Talk About Exciting Deals on the Horizon with Distributors and the Launch of New Products in 2019
20/12/2018
PHOENIX, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Uptick Newswire Stock Day Podcast features Premier Biomedical, Inc. (OTCQB: BIEI ) (“Company”), a research-based publicly traded company that intends to discover and develop [...]
Loop Industries Announces Appointment of Nelson Gentiletti as COO and CFO
20/12/2018
MONTREAL, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Loop Industries, Inc. (Nasdaq: Loop) (“Loop” or the “Company”), a leading technology innovator in sustainable plastic, announced that Nelson Gentiletti will join the Company [...]
Form 8 (DD) - Olivier Bohuon
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - Ian Clark
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA®
20/12/2018
RECORDATI AND HELSINN AGREEMENT FOR THE EXCLUSIVE COMMERCIALIZATION RIGHTS TO LEDAGA ® Milan and Lugano, December 20, 2018 – Recordati and Helsinn announce the signing of a license agreement between Orphan Europe, a [...]
Unum Therapeutics Added to NASDAQ Biotechnology Index
20/12/2018
CAMBRIDGE, Mass., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on the development of novel cellular immunotherapies, today announced that it [...]
Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes
20/12/2018
THE WOODLANDS, Texas, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced topline results from Phase 1 clinical studies of LX2761, an oral sodium-glucose cotransporter type 1 [...]
Form 8 (DD) - Gail Fosler
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Supernus Announces Positive Results from Phase III Study For SPN-812 in Adolescents with ADHD
20/12/2018
Met primary endpoint with robust statistical significance Third positive Phase III study for SPN-812 in patients with ADHD Showed efficacy on both hyperactivity/impulsivity and inattention subscales with statistical [...]
Bellicum Pharmaceuticals Announces Appointment of Judith Klimovsky, M.D., to Board of Directors
20/12/2018
HOUSTON, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood disorders, today [...]
Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
20/12/2018
Phase 3 geographic atrophy program enrollment timeline currently unchanged; program enrollment is expected to restart in Q2 2019 and enrollment completion is expected in Q1 2020 CRESTWOOD, Ky. and WALTHAM, Mass., Dec. [...]
Amicus Therapeutics Announces First Patient Dosed in Phase 3 PROPEL Pivotal Study of AT-GAA in Patients with Pompe Disease
20/12/2018
Global Study to Assess AT-GAA Compared to Standard-of-Care Enzyme Replacement Therapy (ERT) over 52 Weeks CRANBURY, N.J., Dec. 20, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology [...]
FibroGen Announces Positive Topline Results from Three Global Phase 3 Trials of Roxadustat for Treatment of Anemia in Patients with Chronic Kidney Disease
20/12/2018
Primary efficacy endpoints met in all three studies: non-dialysis, incident dialysis, and stable dialysis studies SAN FRANCISCO, Dec. 20, 2018 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN), a leading [...]
Nabriva Therapeutics Submits New Drug Applications to U.S. Food and Drug Administration for Intravenous and Oral Lefamulin to Treat Community-Acquired Bacterial Pneumonia in Adults
20/12/2018
DUBLIN, Ireland, Dec. 20, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical-stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat [...]
miRagen Therapeutics to Present New Cobomarsen Clinical Trial Data for Adult T-Cell Leukemia/Lymphoma and Cutaneous T-Cell Lymphoma at the 11th Annual T-Cell Lymphoma Forum
20/12/2018
BOULDER, Colo., Dec. 20, 2018 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced [...]
Form 8 (DD) - Steven Gillis
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Form 8 (DD) - Sara Mathew
20/12/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]

Pages